ME02405B - Spojevi pirazola као inhibitori sglt1 - Google Patents

Spojevi pirazola као inhibitori sglt1

Info

Publication number
ME02405B
ME02405B MEP-2016-121A MEP2016121A ME02405B ME 02405 B ME02405 B ME 02405B ME P2016121 A MEP2016121 A ME P2016121A ME 02405 B ME02405 B ME 02405B
Authority
ME
Montenegro
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
accordance
intended
Prior art date
Application number
MEP-2016-121A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Fucheng Qu
Nathan Bryan Mantlo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02405(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ME02405B publication Critical patent/ME02405B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MEP-2016-121A 2012-05-10 2013-05-02 Spojevi pirazola као inhibitori sglt1 ME02405B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26
EP13722231.1A EP2850084B1 (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors
PCT/US2013/039164 WO2013169546A1 (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors

Publications (1)

Publication Number Publication Date
ME02405B true ME02405B (me) 2016-09-20

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-121A ME02405B (me) 2012-05-10 2013-05-02 Spojevi pirazola као inhibitori sglt1

Country Status (42)

Country Link
US (2) US8697849B2 (enExample)
EP (1) EP2850084B1 (enExample)
JP (1) JP6148725B2 (enExample)
KR (1) KR101685779B1 (enExample)
AP (1) AP3593A (enExample)
AR (1) AR090806A1 (enExample)
AU (1) AU2013259946B2 (enExample)
BR (1) BR112014026198B1 (enExample)
CA (1) CA2869323C (enExample)
CL (1) CL2014002845A1 (enExample)
CO (1) CO7141429A2 (enExample)
CR (1) CR20140473A (enExample)
CY (1) CY1117912T1 (enExample)
DK (1) DK2850084T3 (enExample)
DO (1) DOP2014000250A (enExample)
EA (1) EA024207B1 (enExample)
EC (1) ECSP14026088A (enExample)
ES (1) ES2588835T3 (enExample)
GT (1) GT201400242A (enExample)
HR (1) HRP20160804T1 (enExample)
HU (1) HUE030414T2 (enExample)
IL (1) IL235427A (enExample)
IN (1) IN2014DN07996A (enExample)
JO (1) JO3136B1 (enExample)
LT (1) LT2850084T (enExample)
MA (1) MA37501B1 (enExample)
ME (1) ME02405B (enExample)
MX (1) MX357058B (enExample)
MY (1) MY177326A (enExample)
NZ (1) NZ700356A (enExample)
PE (1) PE20142399A1 (enExample)
PH (1) PH12014502492A1 (enExample)
PL (1) PL2850084T3 (enExample)
PT (1) PT2850084T (enExample)
RS (1) RS55107B1 (enExample)
SG (1) SG11201407345QA (enExample)
SI (1) SI2850084T1 (enExample)
TN (1) TN2014000410A1 (enExample)
TW (1) TWI579295B (enExample)
UA (1) UA113086C2 (enExample)
WO (1) WO2013169546A1 (enExample)
ZA (1) ZA201407531B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR097890A1 (es) 2013-10-17 2016-04-20 Lilly Co Eli Compuestos de urea
AR098134A1 (es) 2013-11-01 2016-05-04 Lilly Co Eli Compuestos de urea
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
TWI805727B (zh) * 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213296B1 (en) 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
BRPI0313290B1 (pt) * 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
RU2437876C2 (ru) * 2006-05-19 2011-12-27 Тайсо Фармасьютикал Ко., Лтд. Соединение с-фенилглицитола для лечения диабета
ES2548578T3 (es) 2007-12-27 2015-10-19 Kissei Pharmaceutical Co., Ltd. Monosebacato de un derivado de pirazol
PE20120648A1 (es) 2009-02-23 2012-05-31 Taisho Pharmaceutical Co Ltd Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
WO2013169546A1 (en) 2013-11-14
JP2015516419A (ja) 2015-06-11
HRP20160804T1 (hr) 2016-08-12
DK2850084T3 (en) 2016-09-12
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
TW201406773A (zh) 2014-02-16
EP2850084B1 (en) 2016-06-15
GT201400242A (es) 2015-08-27
AU2013259946B2 (en) 2015-09-10
AP2014008044A0 (en) 2014-11-30
MA37501B1 (fr) 2016-11-30
EP2850084A1 (en) 2015-03-25
CY1117912T1 (el) 2017-05-17
PL2850084T3 (pl) 2017-05-31
MX357058B (es) 2018-06-25
CN104284894A (zh) 2015-01-14
JP6148725B2 (ja) 2017-06-14
JO3136B1 (ar) 2017-09-20
PH12014502492B1 (en) 2015-01-12
CL2014002845A1 (es) 2015-01-30
AR090806A1 (es) 2014-12-10
ZA201407531B (en) 2016-05-25
PT2850084T (pt) 2016-08-02
US20130303471A1 (en) 2013-11-14
LT2850084T (lt) 2016-09-12
EA201491852A1 (ru) 2015-02-27
NZ700356A (en) 2016-06-24
CR20140473A (es) 2014-11-21
HUE030414T2 (en) 2017-05-29
EA024207B1 (ru) 2016-08-31
MY177326A (en) 2020-09-11
IL235427A (en) 2016-06-30
TWI579295B (zh) 2017-04-21
CA2869323C (en) 2016-03-29
US9296775B2 (en) 2016-03-29
SG11201407345QA (en) 2014-12-30
CO7141429A2 (es) 2014-12-12
KR20150001798A (ko) 2015-01-06
PH12014502492A1 (en) 2015-01-12
ECSP14026088A (es) 2015-09-30
PE20142399A1 (es) 2015-01-22
US20140162967A1 (en) 2014-06-12
SI2850084T1 (sl) 2016-07-29
CA2869323A1 (en) 2013-11-14
TN2014000410A1 (en) 2015-12-21
IN2014DN07996A (enExample) 2015-05-01
CN104284894B (zh) 2016-02-17
US8697849B2 (en) 2014-04-15
BR112014026198A2 (pt) 2017-06-27
RS55107B1 (sr) 2016-12-30
HK1202542A1 (zh) 2015-10-02
AP3593A (en) 2016-02-15
BR112014026198B1 (pt) 2021-02-02
MA37501A1 (fr) 2016-03-31
AU2013259946A1 (en) 2014-10-16
DOP2014000250A (es) 2014-11-30
ES2588835T3 (es) 2016-11-07
MX2014013615A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
ME02910B (me) Spojevi tetrahidropirolotiazina
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
HRP20171512T1 (hr) Derivati betulina
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
ME02840B (me) Spojevi fenoksietilpiperidina
MX364400B (es) Compuestos de tetraciclina.
JP2015516419A5 (enExample)
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
EA201490573A1 (ru) Соединение бензотиазолона
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
HRP20171514T1 (hr) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt